Executive context
Platform choice (AAV, LVV, adenovirus, retrovirus) drives CMC complexity and unit economics. In the 2025–2033 outlook, AAV is on track for ~54% share by 2033, with tangible upstream gains (10–50×) and downstream recoveries >90% for full capsids. The scaling agenda: move to suspension (target ~94% adoption), standardize analytics, and phase continuous processing where justified by throughput and cost curves. itsallaboutpatents.com
Buyer checklist
• Upstream: HEK293 suspension, transfection efficiency, and lot-to-lot variability controls. itsallaboutpatents.com
• Downstream: platform chromatography + capsid ratio QA to keep recovery >90%. itsallaboutpatents.com
• Scale pathway: pilot → engineering runs → PPQ; identify rate-limiting steps before capex.
• Capacity signals: >$12B facility commitments (2025–2028) and a 2,000+ trial pipeline raising slot scarcity. itsallaboutpatents.com
Link back & next steps
See the Viral Vectors Manufacturing report for segmentation, capacity, and adoption forecasts to 2033, including LVV’s path toward ~33% share. Pricing: $2,100 single-user; delivery in 2–5 hours post-payment. itsallaboutpatents.com
-
Next: See the Biopharma & Life Sciences guide or the full 2025–2033 report for forecasts and detailed methodology.
